{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T14:47:32Z","timestamp":1648651652422},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T00:00:00Z","timestamp":1204243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00108-008-2067-2","type":"journal-article","created":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T16:38:18Z","timestamp":1204303098000},"page":"502-504","source":"Crossref","is-referenced-by-count":2,"title":["Zoledrons\u00e4ure zur Frakturprophylaxe"],"prefix":"10.1007","volume":"49","author":[{"given":"J.D.","family":"Ringe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,29]]},"reference":[{"key":"2067_CR1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K et al. (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N Engl J Med 353: 898\u2013908","journal-title":"N Engl J Med"},{"key":"2067_CR2","first-page":"1","volume":"20","author":"Ringe","year":"2002","unstructured":"Ringe JD (2002) Zoledrons\u00e4ure. Ein neues hochpotentes Bisphosphonat zur Therapie der Tumor-induzierten Hyperkalz\u00e4mie. Arzneimitteltherapie 20: 1\u20136","journal-title":"Arzneimitteltherapie"},{"key":"2067_CR3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/17446651.1.1.15","volume":"1","author":"Ringe","year":"2006","unstructured":"Ringe JD (2006) Zoledronic acid in the treatment of Paget\u2019s disease and other benign bone disorders. Expert Rev Endocrinol Metab 1: 15\u201324","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2067_CR4","first-page":"28","volume":"16","author":"Ringe","year":"2007","unstructured":"Ringe JD, Farahmand P, Dorst A (2007) Intravenous zoledronic acid: A rapid and very effective treatment in localized transient osteoporosis of the hip. Osteologie 16: 28","journal-title":"Osteologie"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-008-2067-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2067-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:12:08Z","timestamp":1558584728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-008-2067-2"}},"subtitle":["HORIZON-Studie (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)"],"short-title":[],"issued":{"date-parts":[[2008,2,29]]},"references-count":4,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["2067"],"URL":"https:\/\/doi.org\/10.1007\/s00108-008-2067-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,29]]}}}